Frontiers in Pediatrics (Oct 2022)

Case report: A novel de novo IGF2 missense variant in a Finnish patient with Silver-Russell syndrome

  • Petra Loid,
  • Petra Loid,
  • Petra Loid,
  • Marita Lipsanen-Nyman,
  • Marita Lipsanen-Nyman,
  • Sirpa Ala-Mello,
  • Katariina Hannula-Jouppi,
  • Katariina Hannula-Jouppi,
  • Katariina Hannula-Jouppi,
  • Juha Kere,
  • Juha Kere,
  • Juha Kere,
  • Outi Mäkitie,
  • Outi Mäkitie,
  • Outi Mäkitie,
  • Outi Mäkitie,
  • Mari Muurinen,
  • Mari Muurinen,
  • Mari Muurinen

DOI
https://doi.org/10.3389/fped.2022.969881
Journal volume & issue
Vol. 10

Abstract

Read online

Silver-Russell syndrome (SRS, OMIM 180860) is a rare imprinting disorder characterized by intrauterine and postnatal growth restriction, feeding difficulties in early childhood, characteristic facial features, and body asymmetry. The molecular cause most commonly relates to hypomethylation of the imprinted 11p15.5 IGF2/H19 domain but remains unknown in about 40% of the patients. Recently, heterozygous paternally inherited pathogenic variants in IGF2, the gene encoding insulin-like growth factor 2 (IGF2), have been identified in patients with SRS. We report a novel de novo missense variant in IGF2 (c.122T > G, p.Leu41Arg) on the paternally derived allele in a 16-year-old boy with a clinical diagnosis of SRS. The missense variant was identified by targeted exome sequencing and predicted pathogenic by multiple in silico tools. It affects a highly conserved residue on a domain that is important for binding of other molecules. Our finding expands the spectrum of disease-causing variants in IGF2. Targeted exome sequencing is a useful diagnostic tool in patients with negative results of common diagnostic tests for SRS.

Keywords